As agents targeting the VEGF-VEGFR axis have been shown to modulate immunosuppressive myeloid cells (4), we reasoned that the combination of anti-VEGF therapy with Imprime may not only have enhanced anti-tumor effects but also have a more profound impact on the immunosuppressive, wound-healing tumor microenvironment than either agent alone. The gene discussed is VEGFA; the disease is neoplasm.